DEXA Bone Density Rate-of-Change: How to Interpret Your Results

What the DEXA Numbers Actually Mean

A DEXA (dual-energy X-ray absorptiometry) scan produces two distinct scores. The T-score compares your bone mineral density to the average peak BMD of a healthy young adult of the same sex. The Z-score compares your BMD to age-matched and sex-matched peers. Both numbers are reported in standard deviation units, but they answer different clinical questions.

The World Health Organization defined the diagnostic thresholds now used universally in postmenopausal women and men aged 50 or older. Those thresholds are based on femoral neck BMD data from the third National Health and Nutrition Examination Survey (NHANES III) [1].

T-Score Classification

| T-Score | WHO Category | |---|---| | -1.0 or above | Normal | | -1.0 to -2.5 | Osteopenia (low bone mass) | | -2.5 or below | Osteoporosis | | -2.5 or below with fragility fracture | Severe osteoporosis |

The National Osteoporosis Foundation (NOF) guideline states: "Pharmacologic treatment should be considered in postmenopausal women and men age 50 and older with a hip or spine T-score of -2.5 or less" [2].

Z-Score and Why It Matters for Younger Patients

Z-scores are preferred in premenopausal women, men under 50, and children. A Z-score below -2.0 is defined as "below the expected range for age" by the International Society for Clinical Densitometry (ISCD) [3]. When a young patient has a Z-score of -2.0 or lower, secondary causes of bone loss (hyperthyroidism, celiac disease, glucocorticoid use, hypogonadism) should be investigated before attributing findings to primary osteoporosis.

Absolute BMD vs. T-Score

The raw BMD number (g/cm²) carries information that T-scores alone can obscure. At the lumbar spine, a typical young-adult female peak BMD is approximately 1.05 g/cm². A value of 0.75 g/cm² at L2-L4 represents a T-score near -2.5. Tracking absolute BMD over serial scans often provides more granular data on rate-of-change than following rounded T-scores, which can mask small but biologically meaningful shifts [4].

Rate-of-Change Interpretation: The Least Significant Change Concept

Single-scan snapshots have limited clinical utility without context. The rate-of-change between two scans is where the actionable signal lives, particularly for patients on therapy or those in high-turnover states like early menopause or androgen-deprivation therapy.

Least Significant Change (LSC)

Every DEXA machine and technologist combination produces measurement variability. The LSC is the minimum BMD change that exceeds this precision error with 95% confidence. ISCD recommends that each facility calculate its own LSC from duplicate scans on at least 30 patients [3].

Typical LSC values in clinical practice are:

• Lumbar spine (L1-L4): 2-4%
• Total hip: 3-5%
• Femoral neck: 4-6%

A change must exceed the LSC before it can be called a true biological change rather than measurement noise. A patient who shows a 2% BMD increase at the lumbar spine after 12 months of alendronate therapy has not necessarily improved if the facility's LSC for that site is 3%.

What Rate of Loss Is Considered Accelerated?

Normal age-related bone loss averages 0.5-1.0% per year in both men and women after peak bone mass is achieved around age 30 [5]. During the first 5-7 years after menopause, women can lose 2-3% per year at the spine, driven by estrogen withdrawal [6]. Loss exceeding 3-5% per year at any major site (spine, total hip, femoral neck) is generally considered accelerated and warrants clinical evaluation.

The HealthRX clinical team uses the following decision framework for serial DEXA interpretation in adults on a longevity-medicine protocol:

Rate-of-Change Tier System:

• Tier 1 (Stable): Less than 1% annualized change from baseline, within LSC. Continue lifestyle optimization and rescreen in 2-3 years.
• Tier 2 (Borderline): 1-3% annualized loss at any major site, or change exceeds LSC but T-score remains above -2.0. Intensify modifiable factors (protein intake, resistance training, vitamin D, calcium). Rescreen in 12-18 months.
• Tier 3 (Accelerated): Greater than 3% annualized loss OR T-score crosses the -2.5 threshold OR FRAX 10-year major fracture risk reaches 20% or above. Initiate pharmacologic discussion and calculate FRAX.
• Tier 4 (Fragility Fracture): Any low-trauma fracture regardless of T-score. Treat as severe osteoporosis immediately per NOF guidelines.

This framework is not a replacement for individualized clinical judgment. It is a triage tool to standardize the initial response to serial scan data.

FRAX Integration: Turning DEXA Data Into Fracture Probability

The FRAX tool (developed at the University of Sheffield, adopted by WHO) converts BMD data plus clinical risk factors into a 10-year probability of major osteoporotic fracture (hip, spine, humerus, forearm) and hip fracture alone [7].

FRAX Treatment Thresholds

The NOF recommends initiating pharmacologic therapy when [2]:

1. T-score is -2.5 or below at hip or spine (regardless of FRAX), OR
2. T-score is between -1.0 and -2.5 (osteopenia range) AND 10-year FRAX major fracture probability is 20% or higher, OR
3. T-score is between -1.0 and -2.5 AND 10-year FRAX hip fracture probability is 3% or higher.

These thresholds are specific to the United States cost-effectiveness model. The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines affirm that FRAX should be calculated at every clinical encounter for patients with low bone mass, and that a prior fragility fracture automatically classifies the patient as high risk independent of T-score [8].

What FRAX Does Not Capture

FRAX underestimates fracture risk in patients with very low BMD below the lowest reference point, recurrent falls, high bone turnover markers, or prolonged glucocorticoid use above 7.5 mg/day prednisone equivalent. Clinicians using FRAX must adjust upward for these factors.

Pharmacologic Intervention: When and What

Bone-protective pharmacology becomes relevant at specific DEXA thresholds and rate-of-change patterns. The first-line agents are bisphosphonates, with alendronate being the most prescribed worldwide.

Alendronate: Dosing and Evidence Base

Alendronate (Fosamax) is approved by the FDA for treatment and prevention of osteoporosis in postmenopausal women and for treatment of osteoporosis in men [9]. The standard dosing is 70 mg orally once weekly (or 10 mg daily).

The Fracture Intervention Trial (FIT), involving 6,459 postmenopausal women with low femoral neck BMD, found that alendronate reduced the risk of clinical vertebral fractures by 55% (relative risk 0.45, P<0.001) over 3 years compared to placebo [10]. Hip fracture risk was reduced by 51% in women with baseline T-scores of -2.5 or below.

Other Bisphosphonates and When to Choose Them

• Risedronate (Actonel): 35 mg weekly. Preferred when alendronate is not tolerated due to GI side effects.
• Zoledronic acid (Reclast): 5 mg IV once yearly. Preferred for patients with swallowing difficulties, adherence problems, or active upper GI disease. The HORIZON-Key Fracture Trial (N=7,765) showed a 70% reduction in vertebral fracture risk and 41% reduction in hip fracture risk over 3 years [11].
• Ibandronate (Boniva): 150 mg monthly. Evidence is strongest for vertebral fracture reduction; hip fracture data are less strong.

Anabolic Agents for Severe or Rapidly Progressive Loss

Patients with T-scores of -3.0 or below, multiple fractures, or continued bone loss despite bisphosphonate therapy may be candidates for anabolic therapy. Teriparatide (Forteo), a recombinant PTH 1-34 fragment at 20 mcg/day subcutaneously, increased lumbar spine BMD by 9.7% over 21 months in the key RCT (N=1,637) compared to 2.8% with alendronate (P<0.001) [12]. Romosozumab (Evenity), a sclerostin inhibitor, demonstrated a 73% reduction in new vertebral fractures versus placebo at 12 months in the FRAME trial (N=7,180) [13].

Hormone Therapy and Bone Density

Estrogen deficiency is the dominant driver of postmenopausal bone loss. Hormone therapy (HT) preserves BMD and reduces fracture risk, though it is not classified as an osteoporosis treatment in most guidelines.

The Women's Health Initiative (WHI) study showed that combined estrogen-progestin therapy reduced hip fracture risk by 34% (hazard ratio 0.66, 95% CI 0.45-0.98) over 5.6 years [14]. The Endocrine Society clinical practice guideline on menopause notes: "For women under age 60 or within 10 years of menopause onset who have bothersome menopausal symptoms, the benefits of hormone therapy generally outweigh the risks, and bone protection is a secondary benefit" [15].

Testosterone and Bone in Men

Men with hypogonadism (total testosterone below 300 ng/dL) lose bone at accelerated rates. Testosterone replacement therapy (TRT) raises BMD at the lumbar spine by approximately 3.7% over 36 months, as shown in the Testosterone Trials (T Trials) bone substudy (N=211, P<0.001) [16]. For men on androgen-deprivation therapy (ADT) for prostate cancer, annual DEXA monitoring is recommended by the American Urological Association, and bisphosphonate or denosumab therapy should begin when T-score reaches -1.0 or below.

Optimal Bone Density Targets in Longevity Medicine

Standard clinical guidelines define treatment thresholds, but longevity-medicine practice asks a different question: what T-score range is associated with the lowest lifetime fracture probability and the best functional outcomes?

The Case for a Higher BMD Target

Epidemiologic data show that fracture risk increases continuously as BMD falls, with no clear threshold effect below the normal range [17]. A 2019 meta-analysis in the Journal of Bone and Mineral Research (25 cohort studies, N=398,610) found that each standard deviation decrease in femoral neck BMD was associated with a 1.57-fold increase in hip fracture risk (95% CI 1.50-1.64) [17].

From a longevity standpoint, the target is not simply "avoid the osteoporosis category." Keeping T-score above -1.0 at femoral neck through the seventh and eighth decades of life is a reasonable longevity target, achievable through resistance training, adequate protein (1.2-1.6 g/kg/day), vitamin D sufficiency (serum 25-OH-D of 40-60 ng/mL), and calcium adequacy (1,000-1,200 mg/day from food and supplements combined).

Bone Turnover Markers as Adjuncts

DEXA captures a static snapshot of BMD. Bone turnover markers give dynamic information about current remodeling activity:

• CTX (serum C-telopeptide): A resorption marker. Normal premenopausal range is approximately 100-400 pg/mL. Values above 600 pg/mL in a postmenopausal woman suggest high resorption rate.
• P1NP (procollagen type I N-terminal propeptide): A formation marker. Values above 80 mcg/L on treatment suggest adequate anabolic response.

The IOF and ISCD recommend using P1NP and CTX as the reference markers for monitoring treatment response, with assessment 3-6 months after initiating antiresorptive therapy [18]. A decline in CTX of 25-30% from baseline within 3-6 months of bisphosphonate initiation confirms biochemical response before the next DEXA scan is due.

Monitoring Intervals and When to Repeat DEXA

Repeating DEXA too frequently wastes resources and exposes patients to unnecessary radiation (approximately 1-10 microsieverts per scan, well below the 50-100 microsievert background dose from a transatlantic flight). Repeating it too infrequently misses actionable rate-of-change data.

ISCD Recommended Intervals

The ISCD 2019 Official Positions state [3]:

• Initiating or changing therapy: Repeat in 1-2 years to assess treatment response.
• Stable on therapy with T-score well above -2.5: Every 2-3 years.
• Post-menopausal women not on therapy with T-score -1.0 to -1.5: Every 3-5 years.
• Normal T-score (-1.0 or above), no risk factors: Every 5-10 years (or may not require repeat at all if baseline is clearly normal in a younger patient).
• High-risk states (glucocorticoid therapy greater than 7.5 mg/day, ADT, aromatase inhibitor therapy): Annually.

Same-Machine Protocol

Rate-of-change interpretation is only valid when both scans are performed on the same machine or a machine cross-calibrated to the original. Manufacturer, software version, and technologist positioning all affect absolute BMD values. The ISCD official positions require documentation of machine serial number and software version at each scan to enable valid serial comparison [3].

Lifestyle Factors That Shift the Rate of Change

Drug therapy operates against a backdrop of lifestyle. Even the best bisphosphonate will be undercut by continued smoking, heavy alcohol use, vitamin D deficiency, or protein malnutrition.

Resistance Training

A 2022 meta-analysis in Osteoporosis International (52 RCTs, N=3,136 postmenopausal women) found that progressive resistance training produced a mean BMD gain of 1.03% at the lumbar spine and 0.89% at the femoral neck over 6-12 months compared to controls (P<0.001) [19]. The effect was larger when training exceeded 3 sessions per week and included axial loading exercises.

Vitamin D and Calcium

Vitamin D and calcium supplementation alone do not prevent fractures in the general population, as the USPSTF 2018 recommendation statement on vitamin D and calcium noted [20]. The benefit of supplementation is concentrated in institutionalized elderly patients or those with documented deficiency. For most ambulatory adults, prioritizing dietary calcium over supplemental calcium reduces the cardiovascular signal associated with high-dose calcium supplements while still meeting skeletal needs.

Protein Intake

The Framingham Osteoporosis Study found that higher protein intake (above 75 g/day) was associated with 6% higher BMD at the femoral neck compared to the lowest quartile (below 47 g/day) over 4 years [21]. Adequate protein supports both osteoblast activity and muscle mass, and sarcopenia and osteoporosis co-occur at high rates in adults over 65.